World's Best Scientists 2026 revealed!
Louis Fehrenbacher

Louis Fehrenbacher

D-Index & Metrics

Medicine

D-Index
84
Citations
80661
World Ranking
14804
National Ranking
7484

Overview

Louis Fehrenbacher is affiliated with Kaiser Permanente in the United States and has contributed extensively to medical research, with a focus on oncology and cancer treatment. Their work spans several main fields including Medicine and Biochemistry, Genetics and Molecular Biology. Within these areas, Fehrenbacher's research has a strong emphasis on subfields such as Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Radiology, Nuclear Medicine and Imaging.

Their research topics cover a range of subjects related to cancer and pharmacology, including:

  • Cancer Treatment and Pharmacology
  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • Estrogen and related hormone effects
  • HER2/EGFR in Cancer Research
  • Radiopharmaceutical Chemistry and Applications
  • Brain Metastases and Treatment

Fehrenbacher has published in several respected venues, with frequent contributions to:

  • Journal of Clinical Oncology
  • Breast Cancer Research and Treatment
  • Cancer Research
  • JNCI Journal of the National Cancer Institute
  • UNC Libraries

Their recent published papers include:

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study (2020, The Lancet Oncology)
  • Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease (2023, Journal of Clinical Oncology)
  • Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (2023, Journal of Clinical Oncology)
  • Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study (2021, Journal of Clinical Oncology)
  • Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer (2023, Journal of Clinical Oncology)

Throughout their career, Fehrenbacher has collaborated frequently with a number of researchers, including:

  • Norman Wolmark
  • Adam Brufsky
  • Sandra M. Swain
  • Charles E. Geyer
  • Eleftherios P. Mamounas

Best Publications

  • BEVACIZUMAB PLUS IRINOTECAN, FLUOROURACIL, AND LEUCOVORIN FOR METASTATIC COLORECTAL CANCER

    Herbert Hurwitz;Louis Fehrenbacher;William Novotny;Thomas Cartwright

  • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

    Edward H. Romond;Edith A. Perez;John Bryant;Vera J. Suman

  • Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

    Melody A. Cobleigh;Charles L. Vogel;Debasish Tripathy;Nicholas J. Robert

  • Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

    Charles L. Vogel;Melody A. Cobleigh;Debu Tripathy;John C. Gutheil

  • Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

    Leonard B. Saltz;John V. Cox;Charles Blanke;Lee S. Rosen

  • Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

    David H. Johnson;Louis Fehrenbacher;William F. Novotny;Roy S. Herbst

  • Atezolizumab Versus Docetaxel for Patients With Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, Open-Label, Phase 2 Randomised Controlled Trial

    Louis Fehrenbacher;Alexander Spira;Marcus Ballinger;Marcin Kowanetz

  • Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer

    Fairooz Kabbinavar;Herbert I. Hurwitz;Louis Fehrenbacher;Neal J. Meropol

  • Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

    Victor G. Vogel;Joseph P. Costantino;D. Lawrence Wickerham;D. Lawrence Wickerham;Walter M. Cronin

  • TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

    Roy S. Herbst;Diane Prager;Robert Hermann;Lou Fehrenbacher

  • Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

    Jennifer K. Litton;Hope S. Rugo;Johannes Ettl;Sara A. Hurvitz

  • Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer

    Kathy D. Miller;Linnea I. Chap;Frankie A. Holmes;Melody A. Cobleigh

  • Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial

    Bernard Fisher;James Dignam;Norman Wolmark;D Lawrence Wickerham

  • Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07

    J. Philip Kuebler;H. Samuel Wieand;Michael J. O'Connell;Roy E. Smith

  • EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

    Alberto F. Sobrero;Joan Maurel;Louis Fehrenbacher;Werner Scheithauer

  • Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: NSABP B-31

    Elizabeth Tan-Chiu;Greg Yothers;Edward Romond;Charles E. Geyer

  • Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    David R. Gandara;Sarah M. Paul;Marcin Kowanetz;Erica Schleifman

  • Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

    Herbert I. Hurwitz;Louis Fehrenbacher;John D. Hainsworth;William Heim

  • Multinational S tudy o f t he Efficacy a nd S afety o f H umanized Anti-HER2 M onoclonal A ntibody i n W omen W ho H ave HER2-Overexpressing M etastatic B reast C ancer T hat H as Progressed A fter C hemotherapy f or M etastatic D isease

    Melody A. Cobleigh;Charles L. Vogel;Debu Tripathy;Nicholas J. Robert

  • Efficacy a nd S afety o f T rastuzumab a s a S ingle A gent i n First-Line T reatment o f HER2 -Overexpressing M etastatic Breast C ancer

    Charles L. Vogel;Melody A. Cobleigh;Debu Tripathy;John C. Gutheil

Frequent Co-Authors

Norman Wolmark
Norman Wolmark University of Pittsburgh
Sandra M. Swain
Sandra M. Swain Georgetown University Medical Center
Joseph P. Costantino
Joseph P. Costantino University of Pittsburgh
Adam Brufsky
Adam Brufsky University of Pittsburgh
Soonmyung Paik
Soonmyung Paik Yonsei University
Eleftherios P. Mamounas
Eleftherios P. Mamounas University of Florida Health
Patricia A. Ganz
Patricia A. Ganz University of California, Los Angeles
Charles E. Geyer
Charles E. Geyer University of Pittsburgh
Julien Mazieres
Julien Mazieres Paul Sabatier University
David R. Gandara
David R. Gandara University of California, Davis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in the healthcare field can open up a wide range of rewarding careers beyond traditional medical degrees. For those seeking a hands-on role, direct admit nursing programs offer a streamlined entry into nursing without the need for a separate application after general studies.

If you are interested in the administrative side of healthcare, a growing option is medical billing and coding. Many students look for medical billing and coding online schools that accept financial aid, making it more accessible and affordable to launch a career in this essential field.

Prospective nurses may wonder about entrance exams. Not every program requires the TEAS or HESI exams—learn more about whether you need to take these tests with resources like do i need to take the teas test for lpn.

Those interested in leadership or management can consider earning a healthcare administration degree. There are a range of online health administration programs designed for busy professionals who want to advance their careers in the healthcare industry.

Best Scientists Citing Louis Fehrenbacher

Trending Scientists

Recently Published Articles